STA
HALO icon

Summit Trail Advisors’s Halozyme HALO Stock Holding History

Summit Trail Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$419K Sell
6,482
-124
-2% -$8.74K 0.01% 1219
2025
Q4 		$445K Buy
6,606
+3,125
+90% +$210K 0.01% 1109
2025
Q3 		$255K Buy
+3,481
New +$231K ﹤0.01% 1241
2018
Q1 		– Sell
-176
Closed -$3K – 937
2017
Q4 		$3K Buy
+176
New +$3.24K ﹤0.01% 1545

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Trail Advisors's HALO Position: Q1 2026 in Review

Summit Trail Advisors reduced its Halozyme (HALO) stake by 1.9% in Q1 2026, selling an estimated $8.74K and leaving 6,482 shares worth $419K. The position accounts for 0.01% of the portfolio, ranked #1219.

Summit Trail Advisors first reported a position in HALO in Q4 2017 and has held it in 4 quarters since. The position peaked at $445K in Q4 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Summit Trail Advisors held 6,482 shares of Halozyme worth $419K as of Q1 2026.
  • Summit Trail Advisors sold 124 Halozyme shares in Q1 2026, an estimated $8.74K.
  • Halozyme made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1219 holding.
  • Summit Trail Advisors first reported a position in Halozyme in Q4 2017 and has held it in 4 quarters since.
  • Summit Trail Advisors's Halozyme position peaked at $445K in Q4 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.